Transport for biological material helps Cellbox raise a €5 million Series A
Cellbox Solutions, a German warm-chain logistics technology company, has completed the final closing of its Series A financing, bringing the total to €5 million – the company will develop its business model and expand its offering to include integrated logistics solutions for sensitive biological materials. Following the first closing of approximately €3.5 million in March […] The post Transport…
Cellbox Solutions, a German company specializing in warm-chain logistics technology for biological materials, has successfully closed its Series A financing round, raising €5 million. This brings the company's total funding to €5 million, with the funds earmarked for expanding its business model and offering integrated logistics solutions for sensitive biological materials.
Following the initial €3.5 million investment round in March 2026, Cellbox Solutions has drawn in additional investors, including members of Baltic Business Angels Invest GmbH, as well as existing investors NRW.BANK and Fraunhofer Venture. The company's founder and CEO, Prof. Dr. Kathrin Adlkofer, emphasized their strong foundation in controlled transport of living biological materials, which will be expanded with the new financing.
The €5 million Series A round aims to develop Cellbox Solutions' technology platform, which includes portable CO₂ incubators (Cellbox and Cellbox Shipper) for transporting living cells, organoids, tissues, and other advanced biological materials under controlled physiological conditions. With over 400 Cellbox systems currently on the market, the company is well-positioned to grow its commercial offering, focusing on strategic partnerships and expanding into Europe, Asia, and North America.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
